Mesa Laboratories (MLAB) Q2 2027 earnings review
Mesa Labs fixes sterilization shipping, but its outlook slows growth
Mesa Laboratories fixed most of its sterilization shipping bottlenecks and expanded profit margins, while its life sciences divisions shrank. Total revenue rose 3% from a year ago, or 5% excluding the genetic testing unit it is scaling back, and cash profit excluding one-offs climbed 21%. Chief executive Dr. Siddhartha Kadia issued his first full-year outlook, which by our math leaves second-half revenue growing 1% and cash profit dipping 5%.
| Sales excluding Clinical Genomics | $52.2M +5.2% from a year ago (total sales +2.6%) |
|---|---|
| Cash profit, excluding one-offs | $17.3M +21.1% from a year ago (27.8% of sales) |
| Net debt to annual cash profit | 1.75x down from 1.85x last quarter and 3.02x a year ago |
| Full-year revenue outlook | $250–255M first outlook issued: 0% to 2% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the sterilization division is shipping reliably again, margins expanded before October's cost cuts even began, and debt paydown hit the year-end leverage target six months early. One caution: export delays still hurt biopharma hardware, and the cautious second-half plan reflects deliberate cuts to low-margin genomics accounts plus new Asian sales hiring.
The question now is whether the flat second-half outlook is just chief executive caution and planned genomics cuts, or a sign that underlying demand in sterilization and biopharma is stalling. If demand is healthy, sales outside genomics will keep growing near 5% while cost savings lift margins; if not, reinvesting savings into new sales reps will weigh on second-half profit. Next quarter's revenue outside genomics and the overdue backlog figure will tell.
🐂 Bull Case
Sterilization Shipments Rebound Against an Easy Comparison
Sterilization and Disinfection Control (SDC), which makes biological indicators that test whether hospital and factory equipment is sterile, brings in two-fifths of revenue. After missing shipments last quarter, chief executive Dr. Siddhartha Kadia said the division is shipping more reliably and "resolved the production issues underlying the delays for most product lines".
Division sales from businesses owned a year ago rose 14.6% to $25.3 million, lifting twelve-month revenue to a record $103.9 million. Its gross margin rose 2.6 percentage points because it spent less on outside contractors, and U.S. regulators inspected its Montana plant with zero violations. However, last year's second quarter was depressed by factory delays, so first-half growth was a calmer 4.9%.
What to watch: the dollar level of overdue sterilization orders in the quarterly filing or conference call. A falling backlog alongside steady shipments would prove the factory fix is permanent rather than a one-quarter catch-up.
Lower Production and Overhead Costs Lifted Margins
Mesa is turning modest sales growth into much larger profit gains by cutting factory and office expenses. Even though total revenue grew just 2.6% from a year ago, operating profit jumped 77.6% to $8.4 million.
- Cost of making products: 36.0% of revenue, down 2.5 percentage points from a year ago
- Operating expenses (sales, research and overhead): 50.5% of revenue, down 3.2 percentage points
- Operating profit excluding one-offs and non-cash charges (AOI): $17.3 million, or 27.8% of revenue, up from 25.1% a year ago
Gross margin improved in its sterilization unit as outside contractor bills rolled off, and in its biopharma division as customers bought more high-margin test supplies. Stock-based pay also fell by $0.4 million. Because these savings arrived before the new October cost-cutting plan even started, the underlying profit floor is higher.
What to watch: second-half operating expenses as management reinvests $4.3 million of annual savings into Asian sales teams. Holding operating profit excluding one-offs above 26% of revenue would show the new spending is not eating up the factory gains.
Debt Paydown Reaches Year-End Target Early
Finance chief John Sakys had aimed to bring net debt down to between 1.5 and 1.75 times annual cash profit by the end of the fiscal year in March. By paying back $11.4 million of debt this quarter and $20.1 million across the first half, the diagnostics maker hit 1.75 times six months early, down from 3.02 times a year ago.
With the debt load lighter, the board replaced an old 2005 buyback plan with a new $40 million share repurchase authorization running through December 2028, "giving flexibility to repurchase shares opportunistically while we continue to reduce debt". Lower debt also cut quarterly interest bills by $0.7 million from a year ago.
What to watch: actual share repurchases in the third quarter. Buying back stock would begin to reverse the 4.1% dilution from employee stock awards over the past year.
🐻 Bear Case
First Full-Year Outlook Points to Stalling Growth
Kadia issued Mesa's first full-year outlook, calling for $250 million to $255 million in revenue and $66 million to $68 million in cash profit (Adjusted EBITDA), "because a number that our shareholders can count on is worth more than one that flatters a quarter". He also introduced a new metric that strips out Clinical Genomics, the genetic testing unit, which grew 5.2% this quarter.
The numbers inside that plan tell a weaker story than the first-half rebound. After growing revenue 1.8% and cash profit 20.9% in the first six months, the middle of the full-year range leaves second-half revenue up just 0.9% from a year ago by our math, with third-quarter sales flat. Worse, it implies second-half cash profit of $34.2 million, down 4.6% from a year ago by our math.
What to watch: third-quarter revenue excluding Clinical Genomics. If growth outside the shrinking genetics unit slows from this quarter's 5.2% pace, the cautious full-year plan reflects sluggish demand rather than just genomics cuts.
Export Delays and Genomics CutsShrink Life Sciences
Mesa's two life sciences divisions — Biopharmaceutical Development (BPD), which sells drug-testing hardware and supplies, and Clinical Genomics (CG), which sells genetic analysis tools — together make up 37% of revenue and both shrank over 8% from a year ago.
- Biopharmaceutical Development revenue: $12.8 million, down 8.2% from a year ago
- Clinical Genomics revenue: $10.2 million, down 8.8% from a year ago
- Calibration Solutions revenue: $14.1 million, up 3.5% on higher volumes and prices, though gross margin slipped 1.1 percentage points on shipping costs
Sakys said biopharma sales "continued to be impacted by export-control processing delays" on peptide hardware, showing that government shipping hurdles remain unresolved. Meanwhile, the company is "managing the business for profitability rather than scale" in genomics and will "de-emphasize lower-margin products and accounts", which it expects will push genomics revenue down through fiscal 2028.
What to watch: Biopharmaceutical Development revenue in the fourth quarter, when it laps a 29.9% drop from a year ago. A failure to rebound against that easy comparison would mean export delays are costing permanent orders.
Risks this quarter didn't answer
Three standing watch items could not be verified from the earnings release alone and await the conference call or the quarterly Form 10-Q filing.
- Sterilization overdue backlog: the release said shipments rose on most lines, but gave no dollar figure for remaining past-due orders or new bookings.
- Gyrolab research spending: the release did not break out research and development costs to show whether the fiscal 2028 instrument launch is getting new money.
- China revenue split: the release noted a modest genomics dip in China, but left total company sales into China for the quarterly filing.
👓 Other Themes
October Restructuring Funds Asian Sales Push
In October, Mesa approved a restructuring plan that will cut $9.3 million in annual operating costs, including closing its Hamburg, Germany facility when the lease ends in February 2027. Management will reinvest $4.3 million into Calibration Solutions sales reps and Asian commercial teams outside China, leaving $5.0 million in net annual savings by the end of fiscal 2028 after $2.6 million to $3.4 million of second-half charges.
💲 Other KPIs
Currency swings on an internal loan reduced pre-tax profit by $0.2 million this quarter and $0.6 million in the first half, compared with a $6.4 million gain in the first half of last year. To strip out this noise and stock-based pay, Mesa introduced Adjusted EBITDA, which rose 21.1% from a year ago to $17.3 million.
Diluted shares rose 4.1% from a year ago (5.76 million vs 5.54 million) because of employee stock awards with no buybacks to offset them. That dilution held per-share profit growth to 66.7% ($0.75 vs $0.45) even as net income rose 75.3% to $4.3 million.
Total liabilities fell 11.7% over the first six months, down $28.4 million from $241.5 million in March 2026 and down from $251.9 million a year ago. The drop tracks $20.1 million of first-half debt repayments funded by operating cash and a $4.6 million drawdown in cash balances to $22.3 million.
🔮 Guidance
New. The plan calls for 0% to 2% revenue growth for the full year, or 1.4% at the middle of the range. After 1.8% growth in the first half, that leaves about 0.9% growth from a year ago for the second half by our math, as management intentionally shrinks low-margin accounts in Clinical Genomics.
New. The company expects third-quarter sales to be about flat compared with last year's $65.1 million, though revenue excluding Clinical Genomics will grow. By our math, a flat third quarter and the middle of the full-year range leave fourth-quarter revenue up about 1.8% from a year ago.
New. Full-year cash profit excluding one-offs and restructuring charges will grow 5% to 8% from last year's $63.0 million, putting the full-year margin at 26.5% at the middle of the range. Because first-half cash profit already rose 20.9% to $32.8 million, the plan leaves second-half cash profit at $34.2 million by our math, down 4.6% from a year ago as sales investments ramp up.
❓ Key Questions
What is the dollar level of overdue sterilization orders?
Sterilization revenue jumped 14.6% against an easy comparison, and management said most lines are shipping reliably. Without the dollar change in past-due backlog or quarterly bookings, investors cannot tell how much growth came from clearing old orders versus new demand.
How small will Clinical Genomics get after the cuts?
Management is shrinking Clinical Genomics through fiscal 2028 to focus on cancer and drug-response testing at high-volume labs, and created a new revenue metric that excludes the division. Sizing the revenue floor would show when the top-line drag ends.
How much peptide hardware is stuck in export controls?
Biopharmaceutical Development sales fell 8.2% because export-control processing delayed peptide hardware shipments, a problem first flagged two quarters ago. Knowing the dollar value of held orders would clarify whether those sales are delayed or lost.
Why does the outlook imply lower second-half cash profit?
By our math, the middle of the full-year Adjusted EBITDA outlook leaves $34.2 million for the second half, down 4.6% from $35.8 million a year ago. How much of that step-down is the $4.3 million annual reinvestment versus pure caution?